| abstract |
REFERS TO [8- (PHENYLSULFONIL) -3,8-DIAZABICYCLO [3.2.1] OCT-3-IL] (1H-1,2,3-TRIAZOL-4-IL) METHANONE COMPOUNDS OF THE FORMULA (I) WHERE R1, R2, R3, R4 AND R5 ARE EACH H, HALOGEN, C1-C3 ALKYL, C1-C3 HALKYL, AMONG OTHERS; R1 AND R2 OR R2 AND R3 ARE OPTIONALLY JOINTED TO EACH OTHER AND FORM A METHYLENEDIOXY, ETHYLEDIOXY, ETHYLENEXY, AMONG OTHERS. PREFERRED COMPOUNDS ARE: [8- (PHENYLSULFONIL) -3,8-DIAZABICYCLO [3.2.1] OCT-3-IL] (1H-1,2,3-TRIAZOL-4-IL) METHANONE; 1H-1,2,3-TRIAZOL-4-IL [8 - {[2- (TRIFLUORomethyl) PHENYL] SULFONIL} -3,8-DIAZABICYCLO [3.2.1] OCT-3-IL] METHANONE; AMONG OTHERS. IT ALSO REFERS TO A PREPARATION PROCEDURE AND A PHARMACEUTICAL COMPOSITION. SAID COMPOUNDS ARE INHIBITORS OF THE ENZYME ACTIVITY OF AKR1C3, BEING USEFUL FOR THE TREATMENT OF GYNECOLOGICAL, HYPERPROLIFERATIVE, METABOLIC OR INFLAMMATORY DISORDERS |